Amplified fluorogenic immunoassay for early diagnosis and monitoring of Alzheimer’s disease from tear fluid

  • 이소정; 
  • Kim, Eunjung; 
  • Moon, Chae-Eun; 
  • Park, Chaewon; 
  • Lim, Jong-Woo; 
  • 외 6명

초록

Abstract Accurate diagnosis of Alzheimer’s disease (AD) in its earliest stage can prevent the disease and delay the symptoms. Therefore, more sensitive, non-invasive, and simple screening tools are required for the early diagnosis and monitoring of AD. Here, we design a self-assembled nanoparticle-mediated amplified fluorogenic immunoassay (SNAFIA) consisting of magnetic and fluorophore-loaded polymeric nanoparticles. Using a discovery cohort of 21 subjects, proteomic analysis identifies adenylyl cyclase-associated protein 1 (CAP1) as a potential tear biomarker. The SNAFIA demonstrates a low detection limit (236 aM), good reliability (R2 = 0.991), and a wide analytical range (0.320–1000 fM) for CAP1 in tear fluid. Crucially, in the verification phase with 39 subjects, SNAFIA discriminates AD patients from healthy controls with 90% sensitivity and 100% specificity in under an hour. Utilizing tear fluid as a liquid biopsy, SNAFIA could potentially aid in long-term care planning, improve clinical trial efficiency, and accelerate therapeutic development for AD.

제목
Amplified fluorogenic immunoassay for early diagnosis and monitoring of Alzheimer’s disease from tear fluid
저자
이소정; Kim, Eunjung; Moon, Chae-Eun; Park, Chaewon; Lim, Jong-Woo; Baek, Minseok; Shin, Moo-Kwang; Ki, Jisun; Cho, Hanna; Ji, Yong Woo; Haam, Seungjoo
DOI
10.1038/s41467-023-43995-5
발행일
2023-12
저널명
Nature Communications
권
14
호
1